- Home
- ARQT vs RNP Comparison
ARQT vs RNP Comparison
Compare ARQT & RNP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ARQT
- RNP
- Stock Information
- Founded
- ARQT 2016
- RNP 2003
- Country
- ARQT United States
- RNP United States
- Employees
- ARQT N/A
- RNP N/A
- Industry
- ARQT Biotechnology: Pharmaceutical Preparations
- RNP Investment Managers
- Sector
- ARQT Health Care
- RNP Finance
- Exchange
- ARQT Nasdaq
- RNP Nasdaq
- Market Cap
- ARQT 2.0B
- RNP 1.0B
- IPO Year
- ARQT 2020
- RNP N/A
- Fundamental
- Price
- ARQT $16.56
- RNP $21.69
- Analyst Decision
- ARQT Strong Buy
- RNP
- Analyst Count
- ARQT 6
- RNP 0
- Target Price
- ARQT $18.80
- RNP N/A
- AVG Volume (30 Days)
- ARQT 2.7M
- RNP 117.6K
- Earning Date
- ARQT 05-13-2025
- RNP 01-01-0001
- Dividend Yield
- ARQT N/A
- RNP 7.94%
- EPS Growth
- ARQT N/A
- RNP N/A
- EPS
- ARQT N/A
- RNP N/A
- Revenue
- ARQT $196,542,000.00
- RNP N/A
- Revenue This Year
- ARQT $56.60
- RNP N/A
- Revenue Next Year
- ARQT $43.62
- RNP N/A
- P/E Ratio
- ARQT N/A
- RNP N/A
- Revenue Growth
- ARQT 229.74
- RNP N/A
- 52 Week Low
- ARQT $6.99
- RNP $15.52
- 52 Week High
- ARQT $17.75
- RNP $21.27
- Technical
- Relative Strength Index (RSI)
- ARQT 66.30
- RNP 53.59
- Support Level
- ARQT $16.80
- RNP $21.67
- Resistance Level
- ARQT $17.75
- RNP $22.09
- Average True Range (ATR)
- ARQT 1.11
- RNP 0.33
- MACD
- ARQT 0.20
- RNP 0.02
- Stochastic Oscillator
- ARQT 87.94
- RNP 72.63
Stock Price Comparison Chart: ARQT vs RNP
About ARQT Arcutis Biotherapeutics Inc.
Arcutis Biotherapeutics Inc is a medical dermatology company. It is developing treatments for patients with immune-mediated dermatological diseases and conditions. It is leveraging recent advances in immunology and inflammation to develop differentiated therapies against biologically validated targets to solve persistent treatment challenges in serious diseases of the skin. The company's product candidate ZORYVE roflumilast cream, has completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population.
About RNP Cohen & Steers REIT and Preferred and Income Fund Inc.
Cohen & Steers REIT and Preferred Income Fund Inc is a diversified, closed-ended investment management fund. Its investment objective is to provide high current income with capital appreciation as its secondary objective. The Fund invests at least its total assets in common stocks issued by real estate investment trusts (REITs) and preferred securities under normal circumstances.